CompletedNCT03521596
Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS
Studying Waldenström macroglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Marzia VarettoniPavia - IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia
- Intervention
- MRD and clonal evolution(other)
- Enrollment
- 300 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2025
Study locations (14)
- Divisione di Ematologia Ospedale Niguarda, Milan, MI, Italy
- SOS Ematologia Ospedale C. Massaia, Asti, Italy
- IRCCS Istituto Tumori Giovanni Paolo II - UOC Ematologia, Bari, Italy
- AOU Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy
- I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1, Padua, Italy
- A.O. Universitaria Di Parma, Parma, Italy
- Ematologia Policlinico San Matteo, Pavia, Italy
- AO Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy
- Ospedale degli Infermi di Rimini, Rimini, Italy
- Policlinico A. Gemelli Università Cattolica del Sacro Cuore, Roma, Italy
- UOC Ematologia, AOU Senese, Siena, Italy
- A.O. Città della Salute e della Scienza Ematologia Universitaria, Torino, Italy
- Azienda Sanitaria Universitaria Integrata di Udine (A.S.U.I. Udine) - PO S. Maria della Misericordia, Udine, Italy
- Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI, Varese, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03521596 on ClinicalTrials.govOther trials for Waldenström macroglobulinemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07387471Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)AbbVie
- RECRUITINGPHASE2NCT05099471Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaChristian Buske
- RECRUITINGPHASE2NCT06561347Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMMassachusetts General Hospital
- RECRUITINGPHASE2NCT05190705Loncastuximab Tesirine in WMShayna Sarosiek, MD
- RECRUITINGNCT05093153Spanish Registry of Patients With IgM Monoclonal GammopathiesFundación Española de Hematología y Hemoterapía
- ACTIVE NOT RECRUITINGPHASE2NCT04624906Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaSunnybrook Health Sciences Centre
- ACTIVE NOT RECRUITINGPHASE2NCT04273139Ibrutinib + Venetoclax in Untreated WMDana-Farber Cancer Institute
- RECRUITINGPHASE2, PHASE3NCT04061512Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaUniversity College, London